gastric cancer
Conditions
Interventions
Chemotherapy
Sponsors
Department of Surgery Graduate School of Medicine, Kyoto University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histological diagnosis of gastric adenocarcinoma 2) Laparoscopy revealed macro- or microscopic peritoneal dissemination as the only factor for Stage IV 3) Distant metastasis was excluded by image diagnosis 4) No prior therapy for gastric cancer 5) Performance Status (ECOG):0-1 6) Oral intake of S-1 is possible 7) Written informed consent 8) Biology and biochemistry within normal limits
Exclusion criteria
Exclusion criteria: 1)Active bleeding from the tumor 2)Paralysis of intestine or ileus 3)Diarrhea(watery stool) 4)Synchronous multicancer 5)Pleural effusion or ascites requiring control 6)Serious comorbidity including -Serious infection -Uncontrollable diabetes mellitus -Heart failure requireing control -Uncontrolled arrhythmia or angina -Severe phyciatric disease -Interstitial pneumonitis or fibroid lung 7)Myocardial infarction within 6 months 8)Patient who has experienced serious allergy for any drug or polysorbate 80 in the past 9)Patient who is pregnant or in lactation, or wish to become pregnant during this study.Male patient who intends to make someone pregnant during this study 10)Patient who requires continuous use of flucytosine 11)Patient who is judged to be inappropriate as subject to this study by the principal investigator or the doctors in charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the maximum tolerated dose and the recommended dose | — |
Countries
Japan
Contacts
Public ContactHiroshi Okabe
Graduate School of Medicine, Kyoto University Department of Surgery
Outcome results
None listed